Dizal Pharmaceutical (688192.SH) receives USD 600 million upfront payment from AstraZeneca for global licensing of Sunvozertinib

Zhito Finance APP News: Dizal Pharmaceutical (688192.SH) announced that the company has recently received a US$600 million upfront payment from AstraZeneca. The arrival of this payment has effectively strengthened the company's cash reserves and provides strong support for the company to continue advancing the global development and commercialization layout of its innovative pipeline. This receipt is expected to have a positive impact on the 2026 performance and financial condition, with the specific amount subject to audited data.